Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (54) 54
female (52) 52
oncology (48) 48
breast neoplasms - drug therapy (47) 47
index medicus (46) 46
middle aged (46) 46
adult (41) 41
aged (38) 38
treatment outcome (38) 38
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
breast cancer (33) 33
breast neoplasms - pathology (32) 32
neoadjuvant therapy (30) 30
chemotherapy (27) 27
chemotherapy, adjuvant (23) 23
trastuzumab (21) 21
cancer (20) 20
neoplasm staging (18) 18
breast neoplasms - surgery (17) 17
disease-free survival (16) 16
survival (16) 16
taxoids - administration & dosage (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (15) 15
breast neoplasms - mortality (15) 15
cyclophosphamide - administration & dosage (15) 15
drug administration schedule (14) 14
prognosis (14) 14
therapy (14) 14
prospective studies (13) 13
antibodies, monoclonal, humanized - administration & dosage (12) 12
adjuvant chemotherapy (11) 11
breast neoplasms - chemistry (11) 11
breast neoplasms - metabolism (11) 11
capecitabine (11) 11
cyclophosphamide (11) 11
receptor, erbb-2 - analysis (11) 11
receptor, erbb-2 - metabolism (11) 11
adjuvant treatment (10) 10
care and treatment (10) 10
docetaxel (10) 10
doxorubicin (10) 10
drug therapy (10) 10
epirubicin - administration & dosage (10) 10
lapatinib (10) 10
neoadjuvant chemotherapy (10) 10
open-label (10) 10
quinazolines - administration & dosage (10) 10
research (10) 10
hematology, oncology and palliative medicine (9) 9
paclitaxel (9) 9
young adult (9) 9
biomarkers, tumor - analysis (8) 8
cancer therapies (8) 8
doxorubicin - administration & dosage (8) 8
health aspects (8) 8
multicenter (8) 8
neoadjuvant therapy - methods (8) 8
paclitaxel - administration & dosage (8) 8
preoperative chemotherapy (8) 8
randomized controlled trials as topic (8) 8
women (8) 8
aged, 80 and over (7) 7
antineoplastic agents - therapeutic use (7) 7
fluorouracil - administration & dosage (7) 7
medicine & public health (7) 7
pathological complete response (7) 7
receptor (7) 7
receptor, erbb-2 - antagonists & inhibitors (7) 7
surgery (7) 7
trial (7) 7
abridged index medicus (6) 6
analysis (6) 6
antibodies, monoclonal, humanized - adverse effects (6) 6
breast neoplasms - genetics (6) 6
clinical trials (6) 6
combination (6) 6
deoxycytidine - administration & dosage (6) 6
deoxycytidine - analogs & derivatives (6) 6
fluorouracil - analogs & derivatives (6) 6
follow-up studies (6) 6
her2 (6) 6
immunohistochemistry (6) 6
plus (6) 6
product development (6) 6
quinazolines - adverse effects (6) 6
quinazolines - therapeutic use (6) 6
time factors (6) 6
antibodies, monoclonal, humanized (5) 5
bevacizumab (5) 5
carcinoma, ductal, breast - drug therapy (5) 5
dose-response relationship, drug (5) 5
efficacy (5) 5
epirubicin (5) 5
further section (5) 5
further section · weitere sektionen (5) 5
germany (5) 5
mastectomy, segmental (5) 5
metastasis (5) 5
oncology, experimental (5) 5
paclitaxel - adverse effects (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
by Cortazar, Patricia, Dr and Zhang, Lijun, PhD and Untch, Michael, Prof and Mehta, Keyur, MBA and Costantino, Joseph P, DrPH and Wolmark, Norman, MD and Bonnefoi, Hervé, Prof and Cameron, David, Prof and Gianni, Luca, Prof and Valagussa, Pinuccia, BS and Swain, Sandra M, MD and Prowell, Tatiana, MD and Loibl, Sibylle, Prof and Wickerham, D Lawrence, MD and Bogaerts, Jan, PhD and Baselga, Jose, Prof and Perou, Charles, PhD and Blumenthal, Gideon, MD and Blohmer, Jens, Prof and Mamounas, Eleftherios P, MD and Bergh, Jonas, Prof and Semiglazov, Vladimir, Prof and Justice, Robert, MD and Eidtmann, Holger, MD and Paik, Soonmyung, MD and Piccart, Martine, Prof and Sridhara, Rajeshwari, PhD and Fasching, Peter A, Prof and Slaets, Leen, PhD and Tang, Shenghui, PhD and Gerber, Bernd, Prof and Geyer, Charles E, MD and Pazdur, Richard, MD and Ditsch, Nina, MD and Rastogi, Priya, MD and Eiermann, Wolfgang, Prof and von Minckwitz, Gunter, Prof
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Summary Background Pathological complete response has been proposed as a surrogate endpoint for prediction of long-term clinical benefit, such as disease-free... 
Internal Medicine | PRIMARY SYSTEMIC THERAPY | MEDICINE, GENERAL & INTERNAL | DOSE-INTENSIFIED CHEMOTHERAPY | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | NEOADJUVANT CHEMOTHERAPY | TRASTUZUMAB | CYCLOPHOSPHAMIDE | DOXORUBICIN | DARBEPOETIN ALPHA | PREPARE TRIAL | Humans | Middle Aged | Treatment Outcome | Randomized Controlled Trials as Topic | Breast Neoplasms - therapy | Carcinoma, Ductal, Breast - therapy | Disease-Free Survival | Neoplasms, Hormone-Dependent - therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Adult | Carcinoma, Ductal, Breast - pathology | Female | Chemotherapy, Adjuvant | Trastuzumab | Preoperative Care - methods | Breast cancer | Research | Medical case management | Patient outcomes | Oncology, Experimental | Cancer | Studies | Chemotherapy | Drug therapy | Cancer therapies | Surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
by von Minckwitz, Gunter, Prof and Schneeweiss, Andreas, Prof and Loibl, Sibylle, Prof and Salat, Christoph, MD and Denkert, Carsten, Prof and Rezai, Mahdi, Prof and Blohmer, Jens U, Prof and Jackisch, Christian, Prof and Paepke, Stefan, MD and Gerber, Bernd, Prof and Zahm, Dirk M, MD and Kümmel, Sherko, MD and Eidtmann, Holger, MD and Klare, Peter, MD and Huober, Jens, Prof and Costa, Serban, Prof and Tesch, Hans, Prof and Hanusch, Claus, MD and Hilfrich, Jörn, Prof and Khandan, Fariba, MD and Fasching, Peter A, Prof and Sinn, Bruno V, MD and Engels, Knut, MD and Mehta, Keyur, MBA and Nekljudova, Valentina, PhD and Untch, Michael, Prof
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 747 - 756
Summary Background Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist... 
Hematology, Oncology and Palliative Medicine | LAPATINIB | WOMEN | MULTICENTER | EFFICACY | ONCOLOGY | OPEN-LABEL | COMBINATION | PERTUZUMAB | PLUS TRASTUZUMAB | CHEMOTHERAPY | PATHOLOGICAL COMPLETE RESPONSE | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Carboplatin - adverse effects | Triple Negative Breast Neoplasms - chemistry | Carboplatin - therapeutic use | Triple Negative Breast Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Aged | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Crosslinked polymers | Breast cancer | Product development | Antineoplastic agents | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
by Baselga, José, Dr and Bradbury, Ian, PhD and Eidtmann, Holger, MD and Di Cosimo, Serena, MD and de Azambuja, Evandro, MD and Aura, Claudia, MD and Gómez, Henry, MD and Dinh, Phuong, MD and Fauria, Karine, PhD and Van Dooren, Veerle, MSc and Aktan, Gursel, MD and Goldhirsch, Aron, MD and Chang, Tsai-Wang, MD and Horváth, Zsolt, MD and Coccia-Portugal, Maria, MD and Domont, Julien, MD and Tseng, Ling-Min, MD and Kunz, Georg, MD and Sohn, Joo Hyuk, MD and Semiglazov, Vladimir, MD and Lerzo, Guillermo, MD and Palacova, Marketa, MD and Probachai, Volodymyr, MD and Pusztai, Lajos, DPhil and Untch, Michael, PhD and Gelber, Richard D, PhD and Piccart-Gebhart, Martine, PhD and NeoALTTO Study Team and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for Surgery and Gastrosurgical Research and Education, Department of Surgery and Institutionen för kliniska vetenskaper, sektionen för kirurgi och kirurgisk gastroforskning, Avdelningen för kirurgi and Sahlgrenska Academy
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
by Untch, Michael, Prof and Loibl, Sibylle, MD and Bischoff, Joachim, MD and Eidtmann, Holger, MD and Kaufmann, Manfred, Prof and Blohmer, Jens-Uwe, Prof and Hilfrich, Jörn, Prof and Strumberg, Dirk, Prof and Fasching, Peter A, Prof and Kreienberg, Rolf, Prof and Tesch, Hans, Prof and Hanusch, Claus, MD and Gerber, Bernd, Prof and Rezai, Mahdi, MD and Jackisch, Christian, Prof and Huober, Jens, Prof and Kühn, Thorsten, Prof and Nekljudova, Valentina, PhD and von Minckwitz, Gunter, Prof and Arbeitsgemeinschaft Gynaekologisch and German Breast Grp GBG and Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group and German Breast Group (GBG)
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 2, pp. 135 - 144
Summary Background We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy.... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | EPIRUBICIN | THERAPY | EFFICACY | ONCOLOGY | SAFETY | CYCLOPHOSPHAMIDE | METASTATIC BREAST-CANCER | PLUS | PACLITAXEL | Antibodies, Monoclonal, Humanized - adverse effects | Breast Neoplasms - surgery | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols | Breast Neoplasms - drug therapy | Young Adult | Taxoids - therapeutic use | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Quinazolines - adverse effects | Female | Neoadjuvant Therapy | Aged | Anthracyclines - therapeutic use | Neoplasm Staging | Trastuzumab | Antimitotic agents | Chemotherapy | Product development | Antineoplastic agents | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
by Gnant, Michael, Prof and Mlineritsch, Brigitte, MD and Stoeger, Herbert, MD and Luschin-Ebengreuth, Gero, MD and Heck, Dietmar, MD and Menzel, Christian, MD and Jakesz, Raimund, Prof and Seifert, Michael, MD and Hubalek, Michael, MD and Pristauz, Gunda, MD and Bauernhofer, Thomas, MD and Eidtmann, Holger, MD and Eiermann, Wolfgang, Prof and Steger, Guenther, MD and Kwasny, Werner, MD and Dubsky, Peter, MD and Hochreiner, Gerhard, MD and Forsthuber, Ernst-Pius, MD and Fesl, Christian, PhD and Greil, Richard, Prof and Austrian Breast Colorectal Canc St and Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 7, pp. 631 - 641
Summary Background Analysis of the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) at 48 months' follow-up showed that addition of... 
Hematology, Oncology and Palliative Medicine | ORAL CLODRONATE | SURVIVAL | BISPHOSPHONATES | ONCOLOGY | TAMOXIFEN | TUMOR-CELLS | GOSERELIN | POSTMENOPAUSAL WOMEN | ANTITUMOR-ACTIVITY | AUSTRIAN BREAST | CHEMOTHERAPY | Follow-Up Studies | Premenopause | Humans | Middle Aged | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Antineoplastic Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Neoplasm Staging | Nitriles - therapeutic use | Triazoles - therapeutic use | Medical colleges | Analysis | Oncology, Experimental | Menopause | Colorectal cancer | Adjuvant treatment | Breast cancer | Research | Tamoxifen | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
by de Azambuja, Evandro, Dr and Holmes, Andrew P, PhD and Piccart-Gebhart, Martine, MD and Holmes, Eileen, PhD and Di Cosimo, Serena, MD and Swaby, Ramona F, MD and Untch, Michael, MD and Jackisch, Christian, MD and Lang, Istvan, MD and Smith, Ian, MD and Boyle, Frances, MBBS and Xu, Binghe, MD and Barrios, Carlos H, MD and Perez, Edith A, MD and Azim, Hatem A, MD and Kim, Sung-Bae, MD and Kuemmel, Sherko, MD and Huang, Chiun-Sheng, MD and Vuylsteke, Peter, MD and Hsieh, Ruey-Kuen, MD and Gorbunova, Vera, MD and Eniu, Alexandru, MD and Dreosti, Lydia, MD and Tavartkiladze, Natalia, MD and Gelber, Richard D, PhD and Eidtmann, Holger, MD and Baselga, José, MD
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1137 - 1146
Summary Background Findings from the randomised phase 3 NeoALTTO trial in women with HER2-positive early breast cancer showed that the combination of lapatinib... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | PREDICTS | WOMEN | THERAPY | EVENTS | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | CHEMOTHERAPY PLUS TRASTUZUMAB | Confidence Intervals | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Administration, Oral | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Infusions, Intravenous | Neoplasm Staging | Trastuzumab | Antimitotic agents | Product development | Breast cancer | Antineoplastic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
by Untch, Michael, Prof and Jackisch, Christian, Prof and Schneeweiss, Andreas, Prof and Conrad, Bettina, MD and Aktas, Bahriye, MD and Denkert, Carsten, Prof and Eidtmann, Holger, MD and Wiebringhaus, Hermann, MD and Kümmel, Sherko, MD and Hilfrich, Jörn, Prof and Warm, Mathias, Prof and Paepke, Stefan, MD and Just, Marianne, MD and Hanusch, Claus, MD and Hackmann, John, MD and Blohmer, Jens-Uwe, Prof and Clemens, Michael, Prof and Darb-Esfahani, Silvia, MD and Schmitt, Wolfgang Daniel, MD and Dan Costa, Serban, Prof and Gerber, Bernd, Prof and Engels, Knut, MD and Nekljudova, Valentina, PhD and Loibl, Sibylle, Prof and von Minckwitz, Gunter, Prof and Arbeitsgemeinschaft Gynakologische and German Breast Grp GBG Investigator and German Breast Group (GBG) and Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 345 - 356
Summary Background In metastatic breast cancer, nab-paclitaxel has been shown to significantly increase progression-free survival compared with solvent-based... 
Hematology, Oncology and Palliative Medicine | EVERY 3 WEEKS | WOMEN | ONCOLOGY | CYCLOPHOSPHAMIDE | ALBUMIN-BOUND PACLITAXEL | HIGH-RISK | OPEN-LABEL | SPARC EXPRESSION | DOCETAXEL | PLUS TRASTUZUMAB | PATHOLOGICAL COMPLETE RESPONSE | Breast Neoplasms - surgery | Confidence Intervals | Prognosis | Drug Administration Schedule | Risk Assessment | Humans | Middle Aged | Mastectomy - methods | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Dose-Response Relationship, Drug | Albumins - therapeutic use | Disease-Free Survival | Albumins - adverse effects | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Survival Analysis | Adult | Breast Neoplasms - mortality | Female | Aged | Infusions, Intravenous | Anthracyclines | Cyclophosphamide | Adjuvant treatment | Product development | Breast cancer | Metastasis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
by Gunter von Minckwitz and Michael Untch and Jens-Uwe Blohmer and Serban D. Costa and Holger Eidtmann and Peter A. Fasching and Bernd Gerber and Wolfgang Eiermann and Jörn Hilfrich and Jens Huober and Christian Jackisch and Manfred Kaufmann and Gottfried E. Konecny and Carsten Denkert and Valentina Nekljudova and Keyur Mehta and Sibylle Loibl
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 15, pp. 1796 - 1804
Purpose The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain.... 
PROJECT PROTOCOL B-27 | DOSE-INTENSIFIED CHEMOTHERAPY | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | CYCLOPHOSPHAMIDE | RANDOMIZED PHASE-III | PRIMARY SYSTEMIC TREATMENT | INTERNATIONAL EXPERT PANEL | DARBEPOETIN ALPHA | PREPARE TRIAL | Carcinoma in Situ - chemistry | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Ductal, Breast - mortality | Mastectomy - mortality | Carcinoma, Ductal, Breast - chemistry | Breast Neoplasms - therapy | Young Adult | Breast Neoplasms - chemistry | Anthracyclines - administration & dosage | Time Factors | Aged, 80 and over | Adult | Carcinoma, Ductal, Breast - pathology | Female | Neoadjuvant Therapy | Mastectomy - adverse effects | Chemotherapy, Adjuvant | Biomarkers, Tumor - analysis | Carcinoma in Situ - pathology | Neoplasm Invasiveness | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma in Situ - therapy | Chi-Square Distribution | Randomized Controlled Trials as Topic | Carcinoma, Ductal, Breast - therapy | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Carcinoma in Situ - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
by von Minckwitz, Gunter and Eidtmann, Holger and Rezai, Mahdi and Fasching, Peter A and Tesch, Hans and Eggemann, Holm and Schrader, Iris and Kittel, Kornelia and Hanusch, Claus and Kreienberg, Rolf and Solbach, Christine and Gerber, Bernd and Jackisch, Christian and Kunz, Georg and Blohmer, Jens-Uwe and Huober, Jens and Hauschild, Maik and Fehm, Tanja and Müller, Berit Maria and Denkert, Carsten and Loibl, Sibylle and Nekljudova, Valentina and Untch, Michael and German Breast Grp and Arbeitsgemeinschaft Gynakologische and German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 4, pp. 299 - 309
Bevacizumab added to neoadjuvant combination chemotherapy increased the rate of pathological complete response among patients with HER-2-negative early-stage... 
TRIAL | SURVIVAL | MEDICINE, GENERAL & INTERNAL | THERAPY | TRASTUZUMAB | CYCLOPHOSPHAMIDE | PHASE-III | DOXORUBICIN | DOCETAXEL | PACLITAXEL | Antibodies, Monoclonal, Humanized - adverse effects | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Logistic Models | Epirubicin - administration & dosage | Breast Neoplasms - drug therapy | Disease Progression | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Medication Adherence | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mastectomy, Segmental | Adult | Female | Neoadjuvant Therapy | Aged | Receptor, ErbB-2 | Neoplasm Staging | Angiogenesis Inhibitors - adverse effects | Drugs | Chemotherapy | Usage | Patient outcomes | Breast cancer | Product/Service Evaluations | Drug therapy | Cancer | Mucositis | Invasiveness | Mammography | Cancer therapies | ErbB-2 protein | Lymph nodes | Metastases | Cyclophosphamide | Ultrasonic imaging | Epidermal growth factor | Biopsy | Surgery | Monoclonal antibodies | Epirubicin | Cardiovascular diseases | Vascular endothelial growth factor | Tumors | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights